PRESS RELEASE published on 11/27/2024 at 23:05, 1 year 7 months ago Theralase(R) Release’s 3Q2024 Financial Statements Theralase® Technologies Inc. releases unaudited financial statements for the nine-month period ended September 30, 2024, showcasing key financial and operational results. Conference call scheduled for December 4th Conference Call Financial Statements Operational Results Theralase® Technologies Inc. Study II
BRIEF published on 11/15/2024 at 13:05, 1 year 7 months ago Theralase Technologies conclut un placement privé de 666 400 $CAN Placement Privé Cancer De La Vessie Technologies Théralase Mandats Stade Clinique
BRIEF published on 11/15/2024 at 13:05, 1 year 7 months ago Theralase Technologies Concludes Private Placement of $CAN 666,400 Private Placement Warrants Bladder Cancer Theralase Technologies Clinical Stage
PRESS RELEASE published on 11/15/2024 at 13:00, 1 year 7 months ago Theralase(R) Closes Non-Brokered Private Placement Theralase® Technologies Inc. successfully closes non-brokered private placement offering of units for cancer research and development funding Private Placement Offering Drug Development Clinical Study Cancer Research Theralase® Technologies Inc.
BRIEF published on 11/13/2024 at 00:28, 1 year 7 months ago Theralase Technologies Extends Warrant Expiry to 2027 TSX Venture Exchange Warrant Extension Cancer Treatment Theralase Technologies Pharmaceutical Development
BRIEF published on 11/13/2024 at 00:28, 1 year 7 months ago Theralase Technologies prolonge l'expiration du mandat jusqu'en 2027 Bourse De Croissance TSX Traitement Du Cancer Technologies Théralase Développement Pharmaceutique Prolongation Du Mandat
PRESS RELEASE published on 11/13/2024 at 00:23, 1 year 7 months ago Theralase(R) Extends Warrants Theralase® Technologies Inc. intends to extend the expiry date of 1,000,000 share purchase warrants from Nov 17, 2024, to Nov 17, 2027. This extension is subject to TSXV approval TSX Venture Exchange Expiry Date Extension Theralase Technologies Inc. Share Purchase Warrants Clinical Stage Pharmaceutical Company
BRIEF published on 10/07/2024 at 13:05, 1 year 8 months ago Mises à jour de Theralase sur l'étude clinique sur le cancer de la vessie Approbation De La FDA Étude Clinique Theralase Cancer De La Vessie Ruvidar
BRIEF published on 10/07/2024 at 13:05, 1 year 8 months ago Theralase Updates on Bladder Cancer Clinical Study FDA Approval Clinical Study Theralase Bladder Cancer Ruvidar
PRESS RELEASE published on 10/07/2024 at 13:00, 1 year 8 months ago Theralase(R) Provides Update on Bladder Cancer Clinical Study Theralase® Technologies Inc. provides update on bladder cancer clinical study for BCG-Unresponsive NMIBC CIS using Ruvidar™ drug activated by TLC-3200 Medical Laser System, achieving positive interim results Clinical Study Theralase® Bladder Cancer RuvidarTM BCG-Unresponsive
Published on 06/30/2026 at 00:05, 2 hours 42 minutes ago American Critical Minerals Announces Completion of Warrant Exercise Incentive Program
Published on 06/29/2026 at 23:46, 3 hours 1 minute ago 1933 Industries Reports Third Quarter 2026 Financial Results
Published on 06/29/2026 at 22:01, 4 hours 46 minutes ago AIP Realty Trust Announces Voting Results of Annual General and Special Meeting of Unitholders
Published on 06/29/2026 at 15:00, 11 hours 47 minutes ago Infield Minerals Significantly Expands Land Holdings and Builds Regional Presence at the Detroit Gold Project in Utah
Published on 06/29/2026 at 22:47, 4 hours ago Correction d’un communiqué du 29.06.2026 22:05 CET/CEST - ABIVAX: Résultats positifs de la partie 2 de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les ...
Published on 06/29/2026 at 22:05, 4 hours 42 minutes ago ABIVAX: Résultats positifs de la partie 2 de l’essai de maintenance ABTECT démontrant bénéfice clinique significatif chez des patients atteints de RCH réfractaire et renforçant les données de sécurité
Published on 06/29/2026 at 22:05, 4 hours 42 minutes ago Abivax Reports Positive ABTECT Maintenance Part 2 Results for Obefazimod, Demonstrating Meaningful Clinical Benefit in Refractory UC Patients and Strengthening the Phase 3 Maintenance Safety Database
Published on 06/29/2026 at 20:30, 6 hours 17 minutes ago Shelly Group SE: Annual General Meeting approves dividend of EUR 0.13 per share – shareholders approve all agenda items
Published on 06/29/2026 at 20:00, 6 hours 47 minutes ago IGEL Appoints James Millington as Field CTO for Healthcare in EMEA
Published on 06/29/2026 at 18:30, 8 hours 17 minutes ago Accor and H World Group expand long-term partnership across direct booking and loyalty platforms
Published on 06/29/2026 at 18:30, 8 hours 17 minutes ago Accor et H World Group : extension du partenariat de long terme aux plateformes de réservation directe et de fidélité
Published on 06/29/2026 at 17:45, 9 hours 2 minutes ago Succès de l’émission obligataire de 1,5 milliard d’euros
